Aurora Financial Journal

Grifols, S.A. (GRFS)

NASDAQ · Health care · Pharmaceutical Preparations · Financial statements, TTM figures and earnings dates

In fiscal year 2024 (ended December 31, 2024), Grifols, S.A. reported revenue of €7.21B and net income of €156.9M. Annual financial statements are available for fiscal years 2015 to 2024, taken from the company's filings with the SEC.

Open interactive financials →

Key financials

EURFY2024
2024-12-31		FY2023
2023-12-31		FY2022
2022-12-31		FY2021
2021-12-31		FY2020
2020-12-31
Income statement
Revenue€7.21B€6.59B€6.06B€4.93B€5.34B
Gross profit€2.79B€2.48B€2.21B€1.96B€2.26B
Operating income€1.19B€782.3M€782.4M€595.1M€996.1M
Net income€156.9M€42.3M€185.0M€188.7M€618.5M
Diluted EPS€0.23€0.06€0.27€0.19€0.60
Cash flow
Operating cash flow€902.2M€218.7M−€1.4M€597.0M€1.11B
Capital expenditure€232.5M€224.4M€283.8M€247.4M€280.2M
Free cash flow€669.6M−€5.7M−€285.2M€349.6M€830.2M
Balance sheet
Cash and equivalents€979.8M€529.6M€549.2M€2.68B€579.6M
Total assets€21.41B€20.99B€21.23B€19.23B€15.27B
Total liabilities€12.80B€13.48B€13.25B€11.92B€8.55B
Total debt€2.66B€4.32B€4.04B€330.0M€3.46B
Shareholders' equity€5.88B€5.37B€5.65B€5.52B€5.11B

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in EUR as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full GRFS page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, the statements exactly as filed with the SEC, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open GRFS financials →